Astellas Pharma Inc.
ALPMY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $2,603 | $2,927 | $3,430 | $3,506 |
| - Cash | $188 | $336 | $377 | $316 |
| + Debt | $831 | $920 | $200 | $213 |
| Enterprise Value | $3,246 | $3,512 | $3,253 | $3,403 |
| Revenue | $1,912 | $1,604 | $1,519 | $1,296 |
| % Growth | 19.2% | 5.6% | 17.2% | – |
| Gross Profit | $1,563 | $1,311 | $1,192 | $1,015 |
| % Margin | 81.7% | 81.8% | 78.5% | 78.3% |
| EBITDA | $248 | $195 | $247 | $242 |
| % Margin | 13% | 12.1% | 16.3% | 18.6% |
| Net Income | $51 | $17 | $99 | $124 |
| % Margin | 2.7% | 1.1% | 6.5% | 9.6% |
| EPS Diluted | 28.24 | 9.47 | 54.09 | 67.05 |
| % Growth | 198.2% | -82.5% | -19.3% | – |
| Operating Cash Flow | $195 | $172 | $332 | $258 |
| Capital Expenditures | -$57 | -$82 | -$89 | -$76 |
| Free Cash Flow | $137 | $90 | $244 | $182 |